Commentary: The Multiple Sclerosis Controversy: Is It Escalation or Induction High Efficacy?

被引：2
|
作者：
Coyle, Patricia K. [1 ]
机构：
[1] SUNY Stony Brook, Med Ctr, Dept Neurol, Stony Brook, NY 11794 USA
来源：
NEUROTHERAPEUTICS | 2020年 / 17卷 / 03期
关键词：
THERAPY;
D O I：
10.1007/s13311-020-00869-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 50 条
  • [1] Commentary: The Multiple Sclerosis Controversy: Is It Escalation or Induction High Efficacy?
    Patricia K. Coyle
    Neurotherapeutics, 2020, 17 : 971 - 972
  • [2] Induction or escalation therapy for patients with multiple sclerosis?
    Le Page, E.
    Edan, G.
    REVUE NEUROLOGIQUE, 2018, 174 (06) : 449 - 457
  • [3] Concepts of induction and escalation therapy in multiple sclerosis
    Rieckmann, Peter
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 277 : S42 - S45
  • [4] Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
    Gilles Edan
    Emmanuelle Le Page
    Drugs, 2023, 83 : 1351 - 1363
  • [5] Escalation Versus Induction/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?
    Edan, Gilles
    Le Page, Emmanuelle
    DRUGS, 2023, 83 (15) : 1351 - 1363
  • [6] Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation
    Putzki, Norman
    Stich, Oliver
    Gartzen, Kristina
    Kastrup, Oliver
    Tettenborn, Barbara
    Rauer, Sebastian
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (11) : E105 - E105
  • [7] Induction vs. escalation of therapy for relapsing Multiple Sclerosis: the evidence
    Freedman, Mark S.
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 2) : S250 - S252
  • [8] Induction vs. escalation of therapy for relapsing Multiple Sclerosis: the evidence
    Mark S. Freedman
    Neurological Sciences, 2008, 29 : 250 - 252
  • [9] Assessing efficacy in clinical trials of treatments for multiple sclerosis - Issues and controversy
    Waubant, EL
    Goodkin, DE
    CNS DRUGS, 1996, 6 (06) : 462 - 473
  • [10] Efficacy and safety of natalizumab as escalation and de-escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, N.
    Kollia, K.
    Katsarava, Z.
    Weber, R.
    Igwe, E.
    Woods, S.
    Diener, H.
    MULTIPLE SCLEROSIS, 2007, 13 : S170 - S171
12345